Results 41 to 50 of about 71,533 (257)
(A) Inhibition of subcutaneous MM NCI-H929 tumor growth in 8–12 week old CB.17 SCID mice (n = 10 per group) that were treated twice weekly for 4 weeks with anti-CD38-IFNα(att) or naked anti-CD38 antibody (both at 10 mg/kg), native IFNα (0.4 mg/kg), or ...
James Berenson (3111285) +15 more
core +1 more source
CD9+ B Cells Induce T Follicular Helper Cell Apoptosis to Regulate Germinal Center Regression
A unique subset of CD9+ B cells regulates germinal center B (GC‐B) cell regression by inducing T follicular helper (Tfh) cell apoptosis through multiple signaling pathways, such as ALCAM‐CD6. FOXP1 plays a key role in GC‐B cell differentiation. These findings clarify mechanisms of GC degeneration and termination and offer potential targets for adenoid ...
Wenjing Liao +27 more
wiley +1 more source
This study reveals that NF‐κB1‐driven TRAIP upregulation in ALD correlates with disease severity. Mechanistically, TRAIP directly binds β‐catenin via its CC domain and promotes its K48‐linked ubiquitination and degradation, which is independent of the GSK3β/β‐TrCP pathway.
Zhan Wu +13 more
wiley +1 more source
Metabolite‐driven redox stress governs cancer cell senescence. TPI1 deficiency elevates DHAP, initiating SARM1‐dependent cADPR‐Ca2+ release. Mitochondrial ROS surge subsequently induces DNA damage and senescence, offering a conserved therapeutic target in multiple cancers.
Chunyu Liu +15 more
wiley +1 more source
CHIN117 is a dual cysteinyl leukotriene receptor 1 (CYSLTR1) antagonist and G‐protein‐coupled bile acid receptor 1 (GPBAR1) agonist. In the liver, GPBAR1 and CYSLTR1 are coexpressed by liver sinusoidal endothelial cells (LSECs), HSCs, circulating monocytes/macrophages, and liver resident macrophages (Kupffer cells).
Michele Biagioli +13 more
wiley +1 more source
Role of Anti-CD38 Monoclonal Antibodies in the Treatment of Adult Immune Hematological Diseases
Daratumumab is a first-in-class human anti-CD38 IgG1 monoclonal antibody approved for treating newly diagnosed and relapsed refractory multiple myeloma. Pre-clinical data supported daratumumab's ability to deplete autoantibodies producing plasma cells, B-
Erin H. Yang +5 more
doaj +1 more source
In MYC‐enforced B‐cell lymphoma, SOX5 occupies promoter‐proximal regulatory regions and is associated with reduced chromatin accessibility at the PCNP locus. PCNP repression promotes proliferative remodeling by limiting apoptosis and cell‐cycle restraint.
Yiyou Mao +6 more
wiley +1 more source
We report a super‐resolution strategy that maps cholesterol‐rich membrane domains in whole, intact cells with an effective spatial resolution of ∼40 nm by combining expansion microscopy with a perfringolysin O domain 4 probe. This approach enables direct visualization of the spatial association between CD20 and CD38 complexes and cholesterol‐rich ...
Gang Wen +9 more
wiley +2 more sources
Interference of daratumumab with compatibility testing in blood bank
Plasma cell myeloma accounts for 1% of malignant tumors and 10%–15% of hematopoietic neoplasms. Daratumumab (DARA), a novel targeted immunotherapy drug, was approved by the Food and Drug Administration to treat relapsed/refractory multiple myeloma. DARA,
Rani Premkumar, Siva Deepthi
doaj +1 more source
Catalysis-based inhibitors of the calcium signaling function of CD38
CD38 is a signaling enzyme responsible for catalyzing the synthesis of cyclic ADP ribose (cADPR) and nicotinic acid adenine dinucleotide phosphate; both are universal Ca(2+) messenger molecules.
Hao, Q +29 more
core +1 more source

